AIDS Therapies (Zintevir)

Clinical Results Reported on HIV Integrase Inhibitor

Published in Virus Weekly, November 25th, 1996

Aronex Pharmaceuticals, Inc., The Woodlands, Texas, reported preliminary results from Phase I trials of Zintevir in HIV positive patients.

Zintevir is in a class of HIV integrase inhibiting compounds. Based upon the results, Aronex has been planning follow-up on multiple dose-ranging trials of Zintevir.

A single-dose rising study and a two-week, multiple-dose escalation study, involving 27 HIV positive patients, have been completed. Results indicate that Zintevir, administered at doses up to 6 mg/kg, is extremely well-tolerated. No clinically significant adverse events were reported.

Results also indicate that Zintevir plasma...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Virus Weekly

Source: Virus Weekly (1996-11-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry